District of Columbia Medicaid spending on GLP-1 drugs

How much did District of Columbia Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $28.1 million for GLP-1 drugs paid through District of Columbia Medicaid in 2025, across at least 27,754 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 115 rows of 265, so these figures are floors.

Pharmacies were reimbursed at least $7.2 million for GLP-1 drugs paid through District of Columbia Medicaid in 2026 (quarter 1 only, as posted so far), across at least 7,410 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 41 rows of 83, so these figures are floors.

By year and ingredient

2020at least $1,748,031No data$1,718,202at least $4,046,872at least $1,019,354SuppressedNo dataat least $8,532,459
2021at least $2,815,071No dataat least $1,305,224at least $6,928,747at least $420,207SuppressedNo dataat least $11,469,249
2022at least $5,163,704at least $21,345at least $1,025,075at least $11,451,457at least $274,514SuppressedNo dataat least $17,936,095
2023at least $8,958,738at least $563,856at least $390,768at least $11,455,498at least $105,510SuppressedNo dataat least $21,474,370
2024at least $18,321,420at least $4,107,448at least $36,036at least $9,084,129at least $95,396SuppressedNo dataat least $31,644,428
2025at least $16,525,229at least $6,224,316Suppressedat least $5,354,807at least $18,239SuppressedSuppressedat least $28,122,591
2026 (Q1)at least $4,017,102at least $2,174,041at least $74,411at least $898,031SuppressedSuppressedNo dataat least $7,163,586

By product, 2025

Ozempicat least $15,937,139at least 15,98611 of 41
Rybelsusat least $426,431at least 30311 of 21
Wegovyat least $161,659at least 18024 of 37
Mounjaroat least $5,949,725at least 5,68135 of 76
Zepboundat least $274,591at least 3587 of 22
Liraglutide (generic name listing)SuppressedSuppressed4 of 4
VictozaSuppressedSuppressed2 of 2
Trulicityat least $5,354,807at least 5,23215 of 55
Bydureonat least $18,239at least 142 of 3
SoliquaSuppressedSuppressed3 of 3
XultophySuppressedSuppressed1 of 1

By quarter, 2025

Q1 2025at least $9,022,913at least 8,41030 of 68
Q2 2025at least $7,164,092at least 6,96331 of 70
Q3 2025at least $6,234,724at least 6,35726 of 65
Q4 2025at least $5,700,863at least 6,02428 of 62

By quarter, 2026 (posted so far)

Q1 2026at least $7,163,586at least 7,41041 of 83

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.